With state-of-the-art facilities across Europe, Polpharma Biologics is at the forefront of the next wave in biopharma, leveraging our knowledge, capabilities and footprint to develop innovative solutions for the industry.
Bioceros Cell Line Development / CHOBC® Technology
Bioceros is located in the Utrecht Science Park, a hub for education, research, entrepreneurship and healthcare. The state-of-the-art facility focuses on the development of production cell lines for monoclonal antibodies (mAbs) and other proteins (including laboratory scale processes), as well as the generation of New Biological Entities (NBEs).
Alexander Numan Building, 2nd floor
3584 CM Utrecht
Development and GMP Production of Drug Substance and Drug Product
Located at the heart of one of the most bustling biotechnology, IT and energetics hubs in Poland, our 7,500 square meter R&D and production facility at the Gdańsk Science and Technology Park is one of the most modern biotechnology centers in Europe. In Gdańsk, we provide process development and GMP production of clinical and medium-scale commercial materials, supported by QC, QA and project management functions. Customized formulations for drug product can also be developed in-house and subsequently tested for stability according to ICH standards. All processes, including fill & finish, can be scaled up and internally transferred to mammalian and microbial GMP-certified production facilities or to external partners. The facility utilizes scale-down models, as well as high-throughput mini and regular bioreactor systems for parallel screening.
Gdańsk Science & Technology Park
Trzy Lipy 3 Building A
80-172 Gdańsk / Poland
Duchnice, Poland (Operational in 2020)*
Large-Scale Modular Drug Substance and Drug Product Plant
To serve the growing global demand for biopharmaceuticals, a new commercial-scale GMP production facility for drug substance and aseptic fill & finish of drug product is being built in Duchnice, near Warsaw.
More information coming soon.
*Polpharma Biologics’ CMO partner
bioeq Corporate Headquarters
Based in Zürich, the Swiss company Bioeq IP AG is a biopharmaceutical joint venture between Polpharma Group B.V. and Santo Holding AG (Strüngmann Group) that focuses on the development and commercialization of biosimilars. Bioeq IP AG holds the global rights to FYB 201, a biosimilar to Lucentis® (ranibizumab) and actively drives the development and commercialization thereof.
Contact Polpharma Biologics
For more information on one of our specific facilities or to discuss an upcoming project, contact Polpharma Biologics using the form below.